Paulina Lugo

Ecuadorian woman 🇪🇨,general and breast surgeon, committed to quality breast cancer management.

[Dr Rishabh Jain @DrRishabhOnco]

Breast cancer is entering a chemo-free, ADC-driven, ctDNA-guided era.
ESMO Breast 2026 could quietly redefine practice.

Here are 10 trials you should NOT miss 👇

1️⃣ PHERGain-2
🧬 Early HER2+
👉 Chemo-free dual HER2 blockade strategy
🎯 Can we safely omit chemo?

2️⃣ TRAIN-4
🧬 Early HER2+
👉 Anthracycline-free ± escalation
🎯 Is less more?

3️⃣ DESTINY-Breast11
🧬 Neoadjuvant HER2+
👉 Trastuzumab deruxtecan vs standard
🎯 ADC replacing chemo?

4️⃣ HER2CLIMB-02
🧬 HER2+ metastatic
👉 Tucatinib + Trastuzumab emtansine
🎯 Brain mets control

5️⃣ SATEEN
🧬 Post-Trastuzumab deruxtecan setting
👉 Sequencing strategies
🎯 What after T-DXd?

6️⃣ TROPION-Breast04
🧬 HR+/HER2- metastatic
👉 Datopotamab deruxtecan
🎯 Next ADC wave

7️⃣ DESTINY-Breast06 (updates)
🧬 HER2-low / ultra-low
👉 Expanding Trastuzumab deruxtecan
🎯 Redefining HER2 biology

8️⃣ PERSEVERE
🧬 ctDNA-guided early BC
👉 MRD-based escalation/de-escalation
🎯 Precision adjuvant therapy

9️⃣ lidERA (Giredestrant)
🧬 Early ER+
👉 Giredestrant vs standard ET
🎯 SERDs moving early

🔟 CAMBRIA-2
🧬 ER+ high-risk
👉 Camizestrant
🎯 Endocrine backbone changing?

#OncoTwitter #MedTwitter #BreastCancer #ADC
@myESMO @ESMO_Open @stolaney1 @OncoAlert @OncBrothers @Larvol

[Paulina Lugo @plugol]

@DanielNoboaOk Muy bien, gracias por demostrar su madurez política y reafirmar el compromiso de seguir luchando por un Ecuador mejor; sí se puede , el país lo apoya!

[Yakup Ergün @dr_yakupergun]

CDK4/6 Inhibition Beyond Progression in postMONARCH: Are We Seeing the Full Picture?

💥A great editorial offering a critical look at the use of CDK4/6 inhibitors beyond progression, exploring methodological uncertainties and implications for clinical practice.

https://t.co/eBqeJgsTMP

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Here’s the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (April 28th - May 4th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

[Steve Cai @SteveCaiMD]

Dr. #KatrinaBMitchell sharing
#LactationalMastitis - ICE, Hielo, 冰
#Lactationalabscess - drainage
#milkfistula - Don’t panic, it’s just milk
#benignbreastdiseases
#asbrs2025 @ASBrS annual meeting!

[Paulina Lugo @plugol]

@JAMAOnc @stolaney1 The link is wrong.

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

Isabel Rubio reviews the role of PET, highlighting our recent @EANM_NucMed @SNM_MI guidelines #SGBCC2025

[Jayshree Veeratterapillay @jaysh160]

Absolutely loved this talk by Dr Oliveira calling for nuanced discussions with patients re risk and benefit in the era of neoadjuvant immunotherapy in TNBC. Chronic toxicities and effect on quality of life not to be underestimated.
#SGBCC2025

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

In his review on chemotherapy use in older women with breast cancer, Hans Wildiers @UZLeuven concludes “Every Oncologist should become a geriatric oncologist.” #SGBCC2025 @SIOGorg

[Dr Amol Akhade @SuyogCancer]

Most up to date data on adjuvant cdk 4/6 inhibitors.
Which tumors warrant adjuvant cdk inhibitors as per current data ? Talk by Dr Angela De Michael @SG_BCC #SGBCC2025 @OncoAlert

[Paolo Tarantino @PTarantinoMD]

Nadia Harbeck reviews opportunities for de-escalation in HER2+ eBC, highlighting promising role for several biomarkers (HER2DX, PET, MRI, among others). #SGBCC2025 @SG_BCC

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

The key molecular difference in HER2 low vs ultra low vs null breast cancers is … HER2 RNA expression is present in HER2 low ⁦@SG_BCC⁩

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New randomized phase 3 trial recently published in @NatureMedicine 👉Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive #BreastCancer
🔓https://t.co/c7bxqzlj0I
✍️ @EMittendorfMD @LoiSher @curijoey @lab_kok @Prof_Nadia_H

[Paulina Lugo @plugol]

@KellyMezaMD @LLSusa @doctorpemm @mpdrc @AaronGoodman33 @DrMonicaGuzman @marklewismd @MDAndersonNews @DrMhidalgo @christinemphmd @NarjustFlorezMD Congrats Kelly 🙌🏼👏🏻👏🏻

[Paulina Lugo @plugol]

@DavidBenjaminMD Thanks for show us this disparity ; the comprehensive cancer care include the supportive care , we can’t forget it!

[David J. Benjamin, MD @DavidBenjaminMD]

Credit to @peterbachmd for inspiring us to look at the state of supportive care in oncology.

Now at #ESMO24, we find:

→ Therapeutic trials outnumber supportive care 25 to 1

→ Industry sponsors only 1.4% of supportive care trials

More findings are available at poster 1901P.

[Matteo Lambertini, MD PhD @matteolambe]

Fully agree with super @lab_kok: more @myESMO annual congresses in #Barcelona !!!

#ESMO24 #ESMOAmbassadors @OncoAlert @RebeccaDSing

[Paulina Lugo @plugol]

Excellent!

[Yakup Ergün @dr_yakupergun]

#ESMO24
Stage 1 TNBC treatment algorithm

From David Cescon's wonderful presentation👇

[Paulina Lugo @plugol]

An important contribution in the use of TILs in HER2 early breast cancer.

[Matteo Lambertini, MD PhD @matteolambe]

Congratulations to @vitti10 and colleagues for a great #ESMO24 presentation reinforcing the value of #TILs in early HER2+ early #BreastCancer !!! 💪🇮🇹👏

#ESMOAmbassadors @myESMO @OncoAlert

[Paulina Lugo @plugol]

@Florez_Lab @crisbergerot @OncJournal @NarjustFlorezMD @drteplinsky @LailaAgrawalMD @AbioyeOyepejuMD @oncodaily @LatinasInMed @DanaFarber @COlazagasti Excellent work , congratulations!

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Here’s the most recent #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (August 26th- September 1st, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch